Expression of Endothelin-A-receptor Predicts Unfavourable Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2004 Jul 1

PMID 15226779

Citations 10

Authors

P Wulfing

J Tio

C Kersting

B Sonntag

H Buerger

C Wulfing

U Euler

W Boecker

A H Tulusan

L Kiesel

Affiliations

Soon will be listed here.

Abstract

Endothelin-1 (ET-1) and its receptors (ETAR and ETBR), referred to as the endothelin (ET) axis, are overexpressed in breast carcinomas and appear to influence tumour growth and progression. The objective of this study was to determine the effect of expression of the ET axis in breast carcinomas on response to cytotoxic chemotherapy. The study included 44 patients with locally advanced breast cancer participating in a prospective phase III study evaluating high-dose neoadjuvant chemotherapy of epirubicin and cyclophosphamide. Expression of ET-1, ETAR and ETBR was determined by semiquantitative immunohistochemical analysis of breast cancer tissue from prechemotherapy tru-cut biopsies. Immunohistochemical staining was positive for ET-1 in 61.5%, for ETAR in 35% and for ETBR in 35.9% of breast carcinomas. Pathological response to chemotherapy was significantly decreased in ETAR-positive patients (P=0.002). In total, 50% of ETAR-positive patients as compared to 7.7% of ETAR-negative patients attained pathologically 'no change'. Logistic regression confirmed ETAR as an independent predictive marker for pathological response (P=0.009). These data indicate that increased expression of ETAR in breast carcinomas is associated with resistance to chemotherapy. Determination of ETAR status may serve as a predictive marker for identifying patients less likely to be responsive to conventional chemotherapy.

Citing Articles

Differences in Endothelin B Receptor Isoforms Expression and Function in Breast Cancer Cells.

Halaka M, Hired Z, Rutledge G, Hedgepath C, Anderson M, St John H J Cancer. 2020; 11(9):2688-2701.

PMID: 32201539 PMC: 7066022. DOI: 10.7150/jca.41004.

GPCR Modulation in Breast Cancer.

Lappano R, Jacquot Y, Maggiolini M Int J Mol Sci. 2018; 19(12).

PMID: 30513833 PMC: 6321247. DOI: 10.3390/ijms19123840.

Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Lee H, Hanibuchi M, Kim S, Yu H, Kim M, He J Neuro Oncol. 2016; 18(4):486-96.

PMID: 26995790 PMC: 4799693. DOI: 10.1093/neuonc/now037.

Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.

Dirican A, Kucukzeybek Y, Alacacioglu A, Varol U, Aksun S, Bayoglu I Med Oncol. 2014; 31(4):905.

PMID: 24596030 DOI: 10.1007/s12032-014-0905-8.

Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence.

Tamkus D, Sikorskii A, Gallo K, Wiese D, Leece C, Madhukar B ISRN Oncol. 2013; 2013:385398.

PMID: 23844294 PMC: 3694385. DOI: 10.1155/2013/385398.

References

Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L . Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol. 2002; 61(3):524-32. DOI: 10.1124/mol.61.3.524. View

Bek E, McMillen M . Endothelins are angiogenic. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1):S135-9. DOI: 10.1097/00005344-200036051-00043. View

Yamashita J, Ogawa M, Inada K, Yamashita S, Matsuo S, Takano S . A large amount of endothelin-1 is present in human breast cancer tissues. Res Commun Chem Pathol Pharmacol. 1991; 74(3):363-9. View

Ali H, Dashwood M, Dawas K, Loizidou M, Savage F, Taylor I . Endothelin receptor expression in colorectal cancer. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1):S69-71. DOI: 10.1097/00005344-200036051-00023. View

Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese R . Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15(7):2483-93. DOI: 10.1200/JCO.1997.15.7.2483. View

Rosano L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra M . Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res. 2003; 63(10):2447-53. View

Sinn H, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M . [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. Geburtshilfe Frauenheilkd. 1994; 54(10):552-8. DOI: 10.1055/s-2007-1022338. View

Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra M . Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res. 2002; 62(22):6381-4. View

Eberl L, Egidy G, Pinet F, Juillerat-Jeanneret L . Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1):S354-6. DOI: 10.1097/00005344-200036051-00103. View

10.

Alanen K, Deng D, Chakrabarti S . Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology. 2000; 36(2):161-7. DOI: 10.1046/j.1365-2559.2000.00795.x. View

11.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y . A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332(6163):411-5. DOI: 10.1038/332411a0. View

12.

Kojima K, Nihei Z . Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol. 1995; 4(6):309-15. DOI: 10.1016/s0960-7404(10)80043-x. View

13.

Eberl L, Valdenaire O, Saintgiorgio V, Jeannin J, Juillerat-Jeanneret L . Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer. 2000; 86(2):182-7. DOI: 10.1002/(sici)1097-0215(20000415)86:2<182::aid-ijc6>3.0.co;2-g. View

14.

Salani D, Castro V, Nicotra M, Rosano L, Tecce R, Venuti A . Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol. 2000; 157(5):1537-47. PMC: 1885720. DOI: 10.1016/S0002-9440(10)64791-8. View

15.

Nelson J, Chan-Tack K, Hedican S, Magnuson S, Opgenorth T, Bova G . Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996; 56(4):663-8. View

16.

HAYWARD J, Carbone P, Heusen J, KUMAOKA S, SEGALOFF A, Rubens R . Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977; 35(3):292-8. PMC: 2025288. DOI: 10.1038/bjc.1977.42. View

17.

Bagnato A, Catt K . Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab. 2008; 9(9):378-83. DOI: 10.1016/s1043-2760(98)00094-0. View

18.

Yamashita J, Ogawa M, Sakai K . Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery. 1995; 117(6):601-8. DOI: 10.1016/s0039-6060(95)80001-8. View

19.

Klaassen U, Wilke H, Weyhofen R, Harstrick A, Eberhardt W, Muller C . Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anticancer Drugs. 1998; 9(3):203-7. DOI: 10.1097/00001813-199803000-00002. View

20.

Rubanyi G, Polokoff M . Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994; 46(3):325-415. View